The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma

Clicks: 124
ID: 118933
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #77 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell lymphoma (DLBCL). However, a few trials comparing CHOP plus rituximab (R-CHOP) with CHOP have been conducted in primary gastric DLBCL. Among 93 consecutive patients receiving CHOP or R-CHOP as a first-line chemotherapy at our institution, 38 patients received CHOP and 55 patients received R-CHOP. With a median follow-up time of 48 months, the complete response (CR) rate, event-free survival (EFS), and overall survival (OS) did not differ between two treatment groups (P = 1.000, P = 0.744, and P = 0.213, respectively). The CR rates were 93.9 % for patients receiving CHOP and 92.5 % for patients receiving R-CHOP. The 3-year EFS rates were 86.0 % for patients receiving CHOP and 81.7 % for patients receiving R-CHOP; the 3-year OS rates were 94.7 and 84.7 %, respectively. In a multivariate analysis, The CR rate was affected by the number of extranodal involvements (P = 0.011). The EFS and OS rates were affected by the Lugano stage (P = 0.067 and P = 0.008, respectively). High serum level of β2-microglobulin was associated with worse EFS and OS in patients receiving R-CHOP (P = 0.018 and P = 0.015, respectively). In conclusion, the addition of rituximab was not found to have an impact on patients’ outcomes with primary gastric DLBCL. The β2-microglobulin in primary gastric DLBCL might be able to discriminate the patients’ prognosis who are treated with R-CHOP chemotherapy.
Reference Key
sohn2012annalsthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Byeong Seok Sohn;Sun-Mok Kim;Dok Hyun Yoon;Shin Kim;Dae Ho Lee;Jin-Ho Kim;Sang-Wook Lee;Jooryung Huh;Cheolwon Suh;Byeong Seok Sohn;Sun-Mok Kim;Dok Hyun Yoon;Shin Kim;Dae Ho Lee;Jin-Ho Kim;Sang-Wook Lee;Jooryung Huh;Cheolwon Suh;
Journal Annals of hematology
Year 2012
DOI
doi:10.1007/s00277-012-1512-4
URL
https://link.springer.com/article/10.1007/s00277-012-1512-4
Keywords
oncology hematology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.